Business Context and Reporting Period
This Form 8-K Current Report was filed by Milestone Pharmaceuticals Inc. on November 29, 2019. The company is incorporated in Québec and its common shares trade on The Nasdaq Stock Market LLC under the symbol MIST. The report specifically addresses a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a specific event and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the departure of a director:
- Marco Boorsma resigned from the Board of Directors and all associated committees.
- The resignation became effective on November 29, 2019.
- The Company stated the resignation is not due to any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors beyond the standard disclosure of the director's departure.
Investor Verification Checklist
- Confirm the effective date of Marco Boorsma's resignation (November 29, 2019).
- Verify if a replacement director has been appointed or if a vacancy remains on the Board.
- Review the Company's subsequent filings to ensure no undisclosed disagreements arose post-resignation.
- Check the composition of Board committees to confirm if Mr. Boorsma's departure created vacancies in specific oversight roles.